ABEONA THERAPEUTICS INC. Noncash Contribution Expense
ABEONA THERAPEUTICS INC. (ABEO) reported Noncash Contribution Expense of $509.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashContributionExpense · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. noncash contribution expense for the quarter ending 2026-06-30 was $235.00K, a 14.55% decline year-over-year.
- ABEONA THERAPEUTICS INC. noncash contribution expense for the quarter ending 2026-03-31 was $274.00K, a 15.17% decline year-over-year.
- ABEONA THERAPEUTICS INC. noncash contribution expense for the quarter ending 2025-12-31 was $284.00K, a 27.55% decline year-over-year.
- ABEONA THERAPEUTICS INC. noncash contribution expense for the quarter ending 2025-09-30 was $270.00K, a 34.31% decline year-over-year.
- ABEONA THERAPEUTICS INC. noncash contribution expense for fiscal 2025 was $1.15M, a 25.10% decline from fiscal 2024.
- ABEONA THERAPEUTICS INC. noncash contribution expense for fiscal 2024 was $1.54M, a 268.82% increase from fiscal 2023.
- ABEONA THERAPEUTICS INC. noncash contribution expense for fiscal 2023 was $417.00K.
| Period end | Noncash Contribution Expense 3 month | Noncash Contribution Expense 6 month | Noncash Contribution Expense 9 month | Noncash Contribution Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $235.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $509.00K 10-Q · filed 2026-08-13 | $793.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.06M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $274.00K 10-Q · filed 2026-05-13 | $558.00K derived: sum of 2 quarters · filed 2026-05-13 | $828.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $284.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $554.00K derived: sum of 2 quarters · filed 2026-03-17 | $829.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.15M 10-K · filed 2026-03-17 |
| 2025-09-30 | $270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $545.00K derived: sum of 2 quarters · filed 2026-08-13 | $868.00K 10-Q · filed 2025-11-12 | $1.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $598.00K 10-Q · filed 2026-08-13 | $990.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $323.00K 10-Q · filed 2026-05-13 | $715.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.13M derived: sum of 3 quarters · filed 2026-05-13 | $1.52M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $392.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $803.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.19M derived: sum of 3 quarters · filed 2026-03-17 | $1.54M 10-K · filed 2026-03-17 |
| 2024-09-30 | $411.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $801.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.15M 10-Q · filed 2025-11-12 | $1.25M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $390.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $735.00K 10-Q · filed 2025-08-14 | $843.00K derived: sum of 3 quarters · filed 2025-08-14 | $948.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $345.00K 10-Q · filed 2025-05-15 | $453.00K derived: sum of 2 quarters · filed 2025-05-15 | $558.00K derived: sum of 3 quarters · filed 2025-05-15 | $662.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $213.00K derived: sum of 2 quarters · filed 2025-03-20 | $317.00K derived: sum of 3 quarters · filed 2025-03-20 | $417.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $105.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $209.00K derived: sum of 2 quarters · filed 2024-11-14 | $309.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $204.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |